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Abstract
Herceptin is widely regarded as the most important development in the treatment of breast cancer
since Tamoxifen and the development of the multidisciplinary team (MDT). It is particularly exciting
from an oncological polint of view as it represents success in the emerging field of specific targeted
therapies to specific molecular abnormalities in tumour cells. This review will focus on the nature
of the Her2 overexpression and the role of herceptin in the treatment of early breast cancer.
Introduction
The structure of HER-2
The HER-2 (neu/cerB2) proto-oncogene is located on
chromosome 17 and encodes a 185 kDa transmembrane
tyrosine kinase receptor which exhibits extensive homol-
ogy to the epidermal growth factor receptor [1-5]. It con-
sists of an extracellular domain, a transmembrane domain
and a cytoplasmic tyrosine kinase domain via which it
exerts it's intracellular action (figure 1).
It appears that the receptor is constitutionally active but
on interaction with it's ligand [6,7], heterodimerisation
occurs activating the receptor further [8-11].
The role of Her-2 in health and disease
In normal cells, HER-2 plays a key role in cellular growth
factor signal transduction and is also involved in the reg-
ulation of cell growth, survival and differentiation [12].
The Her-2 oncogene can be activated by point mutations,
gene amplification or over-expression and it is now well
accepted that this predicts for a poor outcome in mamma-
lian breast cancer [13,14] and is associated with ER nega-
tivity and nodal/brain metastasis. Her-2 overexpression
occurs in approximately 20–30% of breast cancers [15]
and is also overexpressed in lung, ovarian and gastric ade-
nocarcinomas [16].
HER2 over expression has also been found to be an inde-
pendent prognostic predictor of overall survival and time
to relapse [15,17,18]. Several authors have reported a
higher frequency of HER2 over expression in ductal carci-
noma  in situ (DCIS) compared with invasive cancer
[19,20] Similarly, Liu et al [20] have observed HER2 over-
expression as determined by gene amplification using
polymerase-chain reaction (PCR)-based techniques in
48% of in situ carcinomas compared with 21% of stage II
invasive breast tumours. These results were also con-
firmed using immunohistochemical techniques (IHC).
Allred et al [19] reported HER2 over expression as meas-
ured by IHC in 56% of cases of pure DCIS (77% in
comedo lesions), in 22% of infiltrating ductal carcinomas
(IDC) associated with DCIS and 15% of IDC not associ-
ated with DCIS. None of the hyperplastic/dysplastic
breast lesions overexpressed HER2. These observations
suggest that HER2 plays a significant role in the genetic
initiation of mammary carcinogenesis rather than in dis-
ease progression [21]. HER2 expression also appears to
show good concordance between the primary tumour and
both synchronous and subsequent metastasis in both the
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intensity and pattern of IHC staining [22,23] suggesting
that the oncogenic overexpression remains stable.
Clinical Her-2 Testing
Accurate measurement of HER2 amplification and/or
overexpression is vital due to the prognostic and potential
therapeutic implications of being HER-2 positive.
Two main methods exist for the determination of HER2
gene amplification and protein expression in breast can-
cer specimens, fluorescence in situ hybridisation or FISH
(direct or indirect) and IHC. The former measures gene
amplification in breast cancer specimens whilst the latter
measures protein expression.
In the FISH technique, fluorescence labelled cDNA probes
for HER2 (chromosome 17 q11.2–q12.0) and chromo-
some 17 centromeres [(chromosome enumeration probe
17 (CEP17)] are used. The HER2 gene appears as a red/
orange signal and the CEP17 appears as a green. A ratio of
HER2:CEP17 copy number > 2 denotes amplification
when taken over an average of at least 60 invasive cancer
cells.
In the IHC technique, membrane staining of malignant
cells is assessed using the appropriate antibody in fixed
tumour blocks. It is a semi-quantitative technique with
the intensity of staining reflecting the amount of protein
present. From the therapeutic standpoint, the recom-
mended scoring system to evaluate IHC staining is shown
in Table 1 below.
This system has been used in pivotal trials [24] evaluating
the efficacy of a humanised anti-HER2 monoclonal anti-
The HER2 receptor dimer transmembrane signal transduction pathway (with kind permission of Roche) Figure 1
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body therapy in woman with advanced breast cancer and
has been approved by the appropriate authorities in the
USA and the EU.
Ridolfi et al (23) tested 750 consecutive invasive carcino-
mas for HER2 overexpression using both IHC and FISH
techniques. He found that whereas the concordance rate
between FISH and IHC (positive = 3+, negative = 1+, 0)
was 98.7%. FISH was positive in 36% of specimens scored
2+ by IHC (Figure 2) which would have been scored neg-
ative by this technique. A pictorial comparison between
the two testing methods is shown in figure 2[25].
Table 1: The IHC scoring system of HER2
Staining pattern Staining score
Membrane staining is observed in < 10% of the tumour cells 0
A partial and faint membrane staining is detected in > 10% of the tumour cells 1+
A weak to moderate complete membrane staining is detected in > 10% of the tumour cells 2+
A moderate to strong complete membrane staining is detected in > 10% of the tumour cells 3+
Those tumours which score 0 or 1+ are regarded as negative, those scoring 2+ are borderline and 3+ are positive.
HER2-positive testing (a) by IHC (courtesy of Dc M. J. Kornstein, Medical College of Virginia) and (b) by FISH Figure 2
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Hoang et al [26] also reported a high concordance rate for
HER2 positivity between IHC score 3+ and FISH (89%).
However, there was a low interobserver reproducibility in
separating 2+ from 3+cases. This data suggests that IHC is
a useful initial test and cases scoring 2+ should be consid-
ered for FISH testing.
Mass from Genetech [27] recently presented the concord-
ance rates between FISH and the clinical trial assay (CTA),
a immunohistochemical technique in 623 samples ran-
domly selected from the two pivotal Herceptin trials. FISH
positivity was observed in 4.2%, 6.7%, 23.9% and 89.3%
of CTA 0, 1+, 2+ and 3+, respectively.
Conflicting results regarding the best antibody to use in
determining the IHC status of HER2 were presented by
Falo  et al [28]and Bartlett et al [29], respectively. The
former found that monoclonal antibody CB11 was more
reliable than the Dako polyclonal antibody compared
against FISH, whereas Bartlett reported a higher accuracy
for the polyclonal antibody (87.4%) compared with the
monoclonal (83.8%). Gancberg et al [30] studied the sen-
sitivity of three frequently used antibodies and found that
the monoclonal antibody TAB250 had the lowest misclas-
sification rate against FISH in 160 breast cancer speci-
mens.
In view of such conflicting results and the significant inter-
observer variation IHC should be performed in standard-
ised reference laboratories with a large caseload. In the
United Kingdom, all laboratories performing IHC as a
predictive test must participate in an external quality
assurance scheme and guidelines recommend that they
should be performing at least 250 assays per year (100 for
Her2 FISH testing. Alternatively, FISH testing could be
performed as the gold standard. The latter option may
need to be introduced gradually until the technique and
required expertise are established in breast cancer centres.
FISH has been described as not only being both more
accurate in determining HER2 status but also is a better
predictor of prognosis and response to Herceptin. In addi-
tion, DNA is more stable than protein, interpretation is
easier and there is less inter-operator error. FISH however
is both more labour intensive and expensive.
For these reasons in the United Kingdom, a two-phase
testing regimen exists for assessing HER2 status. Initial
IHC testing of 0 or 1+ is reported as negative with 3+ being
reported as positive. A score of 2+ is reported as interme-
diate with these cases being referred for FISH to establish
a definitive diagnosis.
The clinical applications of Her2 testing
Does HER2 Overexpression Predict Adjuvant Tamoxifen 
Failure in Patients With Breast Cancer?
Tamoxifen is a selective oestrogen receptor (ER) modula-
tor and has been proven to reduce relapse, death rates and
risk of contralateral breast cancer and as such is probably
the first truly targeted therapy for treating breast cancer
[31]. Tamoxifen failure therefore is an area that generates
intense research.
Both experimental and clinical evidence have indicated
that the HER2 pathway interacts with the ER pathway with
retrospective clinical studies suggesting an inverse rela-
tionship between ER and HER-2 expression. The propor-
tion of patients with ER/HER-2 +ve breast tumours is
approximately 9%.
Preclinical Evidence
Experimental evidence has shown that oestrogen-depend-
ent MCF7 cells that over express HER2 are rendered
tamoxifen resistant and have reduced numbers of ER
[32,33]. The promoter of the HER-2 gene also contains an
oestrogen response element which suppresses HER-2
expression on response to oestrogen and is overexpressed
with tamoxifen [34,35]. Transfection of MCF-7 cells with
the HER-2 coding region has also been shown to render
them tamoxifen resistant [36]. For these reasons, the
HER2 pathway has been investigated as a potential con-
tributor towards Tamoxifen resistance and HER2 has been
proposed as a potential marker of Tamoxifen sensitivity.
It appears that the mechanism for this resistance may rest
in feedback through joint downstream signalling mecha-
nisms. It has already been described that HER-2 trans-
fected MCF-7 cells are tamoxifen resistant but HER-2
overexpression/stimulation leads to ER downregulation,
increased phosphorylation and also increased transcrip-
tional activation [37-39]. In addition, HER-2 downregula-
tion appears to shut down HER-2 initiated MAP kinase
pathways and makes other ER-linked apoptotic pathways
dominant [40]. Supporting this, blocking MAP kinase in
these HER-2 +, ER + cells restores their sensitivity to
tamoxifen. Another feature of interest is that MEKK1, a
downstream Her-2 signalling mediator activates ER and
potentiates the agonist effect of tamoxifen [41]. In this
way, HER-2 positivity may act to convert tamoxifen from
anantagonist to agonist in breast cancer cells.
Clinical Evidence
Many clinical studies have found an association between
HER2 overexpression and Tamoxifen failure in metastatic
breast cancer [42-45] and also a reduced response dura-
tion and survival duration in those treataed with adjuvant
hormonal therapies. The GUN trial [46], revealed that
HER-2 expression not only predicted tamoxifen resistanceInternational Seminars in Surgical Oncology 2008, 5:9 http://www.issoonline.com/content/5/1/9
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but also showed a worse outcome on tamoxifen com-
pared to those who were untreated (possibly because of
the heightened agonist action). Recently a meta-analysis
of seven studies[47] concluded that metastatic breast can-
cer overexpressing HER2 was very likely to be resistant to
Tamoxifen (odds ratio of disease progression, 2.46).
Recent work presented at the San Antonio breast cancer
conference however did not find such an association. In a
large cohort of stage 2 breast cancer patients randomised
to recieve either 2 years of tamoxifen or nothing, no dif-
ference in tamoxifen efficacy was seen in Her2 -ve patients
when compared to those who were Her 2 +ve.
It still remains controversial however as to whether adju-
vant Tamoxifen has beneficial or detrimental effects in
early breast cancer over expressing HER2 [48,48-51]. Five
of six studies so far have shown that treating patients who
are HER2 positive with adjuvant Tamoxifen does not have
a beneficial effect, and Bianco et al [52] have even
reported a detrimental effect.
Among patients receiving adjuvant Tamoxifen, a com-
bined analysis [53] was undertaken of studies with analys-
able data [48,51,52,54] using the number of patients and
the length of median follow up as a weighting factor for
the relative risk of relapse or death per study. This revealed
that HER2 over expression was associated with an
increased the risk of relapse/death by 75% (RR = 1.75).
Such results strongly suggest that over expression of HER2
predicts reduced response to adjuvant tamoxifen in
patients with EBC, but does not exclude benefit in
patients with HER2 and ER/PgR-positive tumours.
Available clinical evidence, although limited, suggests
that the response to aromatase inhibitors in HER-2 posi-
tive breast cancers is superior to tamoxifen. In randomised
studies of ER +ve HER-2 +ve patients treated with either
Tamoxifen or Letrazole, there was a good response in the
letrazole arm compared to a negligible response with
Tamoxifen [55,56]. It is postulated that this may be due to
the fact that aromatase inhibitors effectively reduce the
amount of active oestrogen rendering the ER monomeric
and inactive, whilst the agonist activity of Tamoxifen can
still be activated by MEKK1.
The role of Herceptin in early breast cancer
Herceptin [31] is a chimeric IgG monoclonal antibody
(95% human, 5% murine) developed from the murine
4D5 antibody. It targets the external moiety of the Her2
receptor and prevents activation of the protein (possibly
by preventing dimerisation) thereby preventing prolifera-
tion of breast cancer cells overexpressing Her2.
Pre-clinical Trials
In pre-clinical studies, anti HER2 MABs have been shown
to inhibit the growth of HER2 over expressing tumour
cells.
Harwerth et al, [57] looked at the effects of HER2-specific
MAB administration on the tumorigenic growth of
human HER2 transformed NIH3T3 cells implanted into
athymic nude mice. Two antibodies (FWP51 and FSP77)
inhibited the onset of tumour growth, and led to retarda-
tion of growth of established tumours. They were also
effective in the treatment of transformed tumours estab-
lished from SKOV3 cells [58]. Furthermore, the authors
observed that the combination of the two antibodies,
which react with two distinct regions of the HER2 recep-
tor, was more effective than treatment with either MAB
alone.
Hudziak et al, [59] showed that a MAB directed against the
extracellular domain of p185 HER2 specifically inhibited
the growth of breast tumour derived cells over expressing
the HER2 gene product. They also showed that resistance
to the cytotoxic effect of tumour necrosis factor alpha (a
consequence of HER2 overexpression) was significantly
reduced in the presence of the antibody.
Clinical trials
The initial trials regarding the use of Herceptin were con-
centrated on it's role in the treatment of metastatic breast
cancer with anthracyclines, paclitaxel and doxetaxel. We
will not be elaborating on this further but instead will
concentrate on the evidence for it's use in EBC.
In the neoadjuvant setting, a preliminary small ran-
domised trial showed an excellent pathological CR rate
(67%) when Herceptin was used with a number of chem-
otherapeutic agents (particularly paclitaxel) followed by
combination anthracycline treatment when compared
with standard chemotherapy alone (25%) [60]. Following
these remarkable results, 4 major trials were started
recruiting 13,000 patients to assess the role of Herceptin
further. Each trial used Herceptin for 1 year either in com-
bination with or following chemotherapy and each has
shown a recurrence risk reduction of approximately 50%.
The two USA based trials (NSABBP B-31 and NCCTG
N9831) combined their data showing benefit when Her-
ceptin was used with paclitaxel following 4 courses of
anthracycline [61]. The HERA trial showed similar results
when Herceptin was used alone following standard chem-
otherapeutic regimens with a 46% recurrence risk reduc-
tion, 51% distant recurrence risk reduction and a 24%
reduction in mortality (not significant), which was seen
across all subsets [62]. Recent subgroup analysis has
shown this relapse reduction to be independent of the
nodal status or hormone receptor profile even in thoseInternational Seminars in Surgical Oncology 2008, 5:9 http://www.issoonline.com/content/5/1/9
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patients with a relatively low risk of relapse. The BCIRG
006 trial showed similar benefit with docetaxel following
4 courses of anthracyclines [63]. This trial also showed
benefit with a novel non-anthracycline schedule using
upfront herceptin with docetaxel and carboplatin which
would avoid anthracycline related cardiotoxicity. This lat-
ter schedule however is probably only as effective as
anthracyclines in the 65% of patients whose tumours do
not overexpress topo-isomerase 2, a key target of anthro-
cycline chemotherapy.
Maturation of these trials has also shown a significant sur-
vival benefit at 2 years followup of 34% (HERA) which is
mirrored by the two American trials.
Although these results are undoubtedly very exciting it
should be remembered that the followup is still relatively
short. The optimal duration of Herceptin treatment is also
subject of considerable debate. A 2 year extended treat-
ment arm of the HERA trial is currently underway with
results expected whilst a small Finnish trial has suggested
a mere 9 week upfront course of Herceptin may have the
same benefit as the larger trials [64].
The role of herceptin with adjuvant hormonal therapy
It has already been established that herceptin is an
extremely useful adjuvant therapy in the HER-2 +ve, ER/
PR -ve patient and also that it predicts for tamoxifen resist-
ance. It would therefore seem reasonable to expect that
administering Herceptin plus Tamoxifen to ER+ve HER-2
positive patients may overcome this Tamoxifen resistance.
This has been proved preclinically using the parent anti-
body of Herceptin mAb 4D5 [36]. Several other cell cul-
ture studies have revealed greater growth inhibition using
a combination of Herceptin and Tamoxifen on ER+ve/
HER-2+ve cell lines when compared with each agent in
isolation [36,65] and have also showed that this is only
the case with strongly ER+ve cell lines [66]. Several studies
are currently underway investigating this phenomenon
further.
The cost of Herceptin
Herceptin is not without complications with mild to
moderate adverse effects occuring in approximately 50%
of patients. The most common adverse reactions are
related to the initial infusion particularly fever, chills,
pain, vomiting and headache [24,24,67], and the most
serious adverse reaction is class III/IV cardiac dysfunction.
The NSABBP B-31 trial showed an increase in cardiotoxic-
ity of 3.3% in the Herceptin vs the control arm, and the
HERA trial produced a 1.7% increase in cardiac failure
[68].
Cobleigh et al [69,70] reported cardiac dysfunction in 10
patients (4.7%) nine of whom had received anthracycline
therapy. There was one cardiac-related mortality. Such
data suggest that the combination of anthracycline and
herceptin should be avoided and the left ventricular ejec-
tion fraction should be measured in patients at risk. Her-
ceptin-related cardiac dysfunction varies in severity and
should be treated with standard medical therapy (diuret-
ics, glycosides, ACE inhibitors, etc) and discontinuation
of herceptin therapy should be considered when the risks
outweigh the benefits.
Other adverse reactions include hypersensitivity reactions
and anaphylaxis (rare), pulmonary events including dysp-
noea, bronchospasm and ARDS (rare), haematological
toxicity (leucopenia, thrombocytopenia and anaemia)
and hepatic and renal toxicity. Many of these side effects
are believed to be related to the 5% murine component
located at the FAB end of the antibody. There have been
no reports so far of the development of measurable anti-
bodies to Herceptin inpatients who received the recom-
mended dose.
Herceptin should be avoided in pregnancy as the tera-
togenic risk is as yet unknown and should also be avoided
in breastfeeding and for 6 months afterwards.
Financially, treatment with herceptin and a taxane will
cost approximately £20,000 per patient assuming that the
treatment is stopped ater 18 weeks which does not include
costs associated with testing, and investigation and treat-
ment of cardiac morbidity.
Conclusion
Herceptin has emerged as the single most important treat-
ment for breast cancer in both the metastatic and neoad-
juvant settings, since the emergence of Tamoxifen. It is
particularly exciting since it represents the first truly effec-
tive targeted treatment to molecular abnormalities in
tumour cells. Although the trials are of relatively short fol-
lowup duration, the treatment is associated with rare but
significant side effects and the treatment is not without
cost, Herceptin has undoubtedly made a real difference
for those 25–30% of patients who overexpress the Her2/
neu oncogene. Table 2 summarises the current place for
Herceptin in early breast cancer.
Table 2: The role of herceptin in early breast cancer
ER PR HER-2 Treatment
+ +/- - Tamoxifen/AI
++ / - + A I
- + - Tamoxifen
- - + Herceptin + chemo
--- N o t h i n gInternational Seminars in Surgical Oncology 2008, 5:9 http://www.issoonline.com/content/5/1/9
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In the future the role of combined Herceptin and hormo-
nal therapies will hopefully become more evident which
may further benefit this group of patients.
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